Skip to main content

Bezlotoxumab Disease Interactions

There are 2 disease interactions with bezlotoxumab.

Major

Bezlotoxumab (applies to bezlotoxumab) CHF

Major Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure

Heart failure was reported more frequently with bezlotoxumab than with placebo in two Phase 3 clinical trials, and occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of bezlotoxumab-treated patients and 4.8% (5/104) of placebo-treated patients had heart failure as an adverse reaction during the 12-week study period, and 19.5% (23/118) versus 12.5% (13/104) died, respectively. The causes of death varied and included cardiac failure, infections, and respiratory failure. Therapy with bezlotoxumab should be reserved for use only when the benefit outweighs the risk in patients with a history of CHF.

References

  1. (2016) "Product Information. Zinplava (bezlotoxumab)." Merck & Co., Inc
Moderate

Bezlotoxumab (applies to bezlotoxumab) congestive heart failure

Moderate Potential Hazard, Moderate plausibility.

Bezlotoxumab should be used with caution in patients with a history of congestive heart failure, and it should be reserved for use when the benefits outweigh the risk.

References

  1. (2016) "Product Information. Zinplava (bezlotoxumab)." Merck & Co., Inc

Bezlotoxumab drug interactions

There are 2 drug interactions with bezlotoxumab.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.